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ABSTRACT 
Background: Cardiovascular diseases and dyslipidemia represent a major health issue 
in psychiatry. Many psychotropic drugs can induce a rapid and substantial increase of 
blood lipid levels. Objective: This study aimed to determine the potential predictive 
power of an early change of blood lipid levels during psychotropic treatment on long-
term change and on dyslipidemia development. Methods: Data were obtained from a 
prospective study including 181 psychiatric patients with metabolic parameters 
monitored during the first year of treatment and with adherence ascertained. Blood lipid 
levels (i.e. total- (TC), low-density lipoprotein- (LDL-C), high-density lipoprotein- (HDL-
C), non-high-density lipoprotein- (non-HDL-C)  cholesterol and fasting triglycerides 
(TG)) were measured at baseline and after 1, 3 and/or 12 months of treatment. Results: 
Receiver operating characteristic analyses indicated that early (i.e. after one month of 
psychotropic treatment) increases (≥5%) for TC, LDL-C, TG and non-HDL-C and 
decrease (≥5%) for HDL-C were the best predictors for clinically relevant modifications 
of blood lipid levels after 3 months of treatment (≥30% TC, ≥40% LDL-C, ≥45% TG, 
≥55% non-HDL-C increase and ≥20% HDL-C decrease; sensitivity 70-100%, specificity 
53-72%). Predictive powers of these models were confirmed by fitting longitudinal 
multivariate models in the same cohort (p≤0.03) as well as in a replication cohort (n=79; 
p≤0.003). Survival models showed significantly higher incidences of new onset 
dyslipidemia (TC, LDL-C and non-HDL-C hypercholesterolemia, HDL-C 
hypocholesterolemia and hypertriglyceridemia) for patients with early changes of blood 
lipid levels compared to others (p≤0.01). Conclusion: Early modifications of blood lipid 
levels following prescription of psychotropic drugs inducing dyslipidemia should 
therefore raise questions on clinical strategies to control long-term dyslipidemia. 
INTRODUCTION 
Individuals with severe mental illness, in particular schizophrenia, bipolar and major 
depressive disorders have a 10 to 25-year reduced life expectancy compared to 
subjects from the general population 1-8. Most of this premature mortality has been 
attributed to cardiovascular diseases resulting from the metabolic syndrome 9. Several 
risk factors implying complex mechanisms may explain this excess cardiovascular risk, 
including psychiatric disease-related factors, unhealthy lifestyle, poverty and adverse 
effects of treatment 10, 11. Thus, the use of psychotropic medications such as 
antipsychotics (most atypical but also some typical), mood stabilizers (e.g. lithium and 
valproate) and some antidepressants (e.g. mirtazapine) can increase the risk of 
metabolic disorders including obesity, type 2 diabetes, hypertension and dyslipidemia 12.  
Components of the metabolic syndrome may develop early during psychotropic 
treatment 13-15 and may initiate a steady process leading to cardiometabolic diseases in 
the long-term, highlighting the importance to prospectively monitor metabolic 
parameters during treatment 16. A threshold of 5% weight gain during the first month of 
psychotropic treatment was recently defined as a robust predictor for subsequent 
important weight gain 13. To date, nothing is known about any other early metabolic 
threshold for predicting worsening of cardiometabolic parameters during treatment with 
psychotropic drugs. Dyslipidemia, defined as high LDL-cholesterol (LDL-C) and/or low 
HDL-cholesterol (HDL-C) and/or high triglyceride (TG) levels, constitutes an important 
risk factor for cardiovascular diseases as its prevalence has been shown to reach 55% 
in schizophrenia patients receiving psychotropic drugs 17. This side effect induced by 
psychotropic drugs has long been considered as resulting from psychotropic-drug 
induced weight gain. However, new data revealed that these lipogenic adverse effects 
may occur very early during treatment and may even precede weight gain, displaying 
weight-independent molecular effects in addition to weight-related ones 11, 15, 18 19, 20.  
To our knowledge, only one study investigated the predictive value of early on mid-term 
lipid changes 21. This study observed that a lack of early (i.e. from 6 to 12 weeks) 
elevation in triglyceride concentration of 0.23 mmol/l (20 mg/dL) was predictive of later 
(i.e. from 24 to 28 weeks) lack of substantial triglyceride increase in patients receiving 
olanzapine, ziprasidone or aripiprazole 21. Notably, the latter study was a post-hoc 
analysis of clinical trials examining the effects of specific drugs, with restrictions on the 
number of prescribed drugs, conditions that are not comparable to the usual clinical 
practice. Moreover, the longest treatment duration was of 28 weeks, with no data on 
longer term.  
Although no threshold of serum lipid concentration was defined as being a sign to 
reconsider psychotropic treatment 22, the National Cholesterol Education Program 
(ATPIII) states that increases of 50 mg/dL (0.57 mmol/l) for TG, of 40 mg/dL (1.04 
mmol/l) for total cholesterol (TC) and of 30 mg/dL (0.77 mmol/l) for low-density 
lipoprotein cholesterol are considered as sufficient for a categorical-risk change from 
“borderline-high” to “high” and are therefore clinically significant 23. When referring to the 
upper values of the clinical ranges, these increases correspond to approximately 29% of 
TG (0.57/2), 21% of TC (1.04/5) and 26% of LDL-C (0.77/3).  
Because of the high mortality and morbidity associated with dyslipidemia, an early 
detection of patients who are at higher risk of developing an important change in plasma 
lipid levels during psychotropic treatment is of major clinical relevance. In the present 
study, we sought to determine, in a cohort of patients taking psychotropic medication 
with adherence ascertained by therapeutic drug monitoring, how plasma lipid changes 
during the first month of treatment could predict mid- and long-term plasma lipid 
changes and new onset dyslipidemia (NOD). 
 
 
 
 
 
 
 
 
  
METHODS 
Study design 
Since 2007, a longitudinal observational study is ongoing in the Department of 
Psychiatry of the Lausanne University Hospital. Patients starting a psychotropic 
treatment with amisulpride, aripiprazole, clozapine, haloperidol, lithium, mirtazapine, 
olanzapine, quetiapine, risperidone and/or valproate were included, as described in the 
flowchart (S1 Figure). The present study included patients with informed consent from 
an ongoing pharmacogenetic study (PsyMetab) as described elsewhere 24. In addition, 
data of patients in the clinical follow-up (PsyClin) were obtained in the hospital or in 
outpatients centers during a medical examination based on the department guideline for 
metabolic follow-up performed on a routine basis 16. Monitoring for physical health risk 
factors include prospective assessments of body mass index (BMI), waist 
circumference, fasting glucose, lipid profile, blood pressure and tobacco smoking during 
treatment 25. When a treatment was stopped for more than 2 weeks, or if a drug was 
replaced by another drug on the list, the follow-up was restarted from baseline. In case 
of the introduction of a second studied drug, the follow-up was restarted and the last 
introduced drug considered as the main treatment. Because of the noninterventional 
post hoc analysis study design, no informed consent was requested from the clinical 
follow-up patients. Both studies were approved by the ethics committee of the Lausanne 
University Hospital. 
Only patients with available lipid levels at least at baseline, first month (15 to 45 days of 
treatment; median of 32 days (interquartile range (IQR): 28-36)) and another month, i.e. 
either month 3 (45 to 135 days of treatment; median of 94 days (IQR: 88-106)) or month 
12 (136 to 535 days of treatment; median of 365 days (IQR: 277-392)) without any lipid-
lowering drug (S1 Table) were included for the determination of early thresholds.  For 
analyses of NOD incidence, only patients without dyslipidemia at baseline were 
included (S1 Figure; see Supplementary Material (paragraph 1.2)). 
Statistical analyses 
Marginal analyses were conducted using Wilcoxon-Mann-Whitney rank-sum tests to 
compare continuous variables across groups and Chi-squared and Fisher’s exact tests 
to assess associations among categorical variables. 
Short-term lipid changes as predictors of long-term lipid changes in the discovery 
sample 
To assess the predictive value of an early change of blood lipid levels (i.e. during the 
first month of treatment) on long-term lipid change (3 and 12 months), sensitivity, 
specificity, positive predictive value and negative predictive value were calculated using 
the pROC R package 26. Sensitivity was defined as the percentage of patients predicted 
as high-risk patients among all truly high-risk patients. Specificity was defined as the 
percentage of patients predicted as low-risk patients among all truly low-risk patients.  
Thresholds for early lipid changes were examined in 5% increments (from 5 up to 35, 
whenever the number of observations was sufficient) to find the best predictors for long-
term increases of TC, LDL-C, TG and non-HDL-C increase and HDL-C decrease 
(increments of 5% from 5 up to 55, whenever the number of observations was 
sufficient). These analyses allowed assessing the best relation between sensitivity and 
specificity to find acceptable thresholds for short and long term blood lipid changes. 
More details in Supplementary Material (paragraph 1.4.1). 
  
Confirmatory analyses in discovery and replication samples 
The nlme package of R was used to fit a linear mixed effect model on long-term lipid 
changes adjusted for age, gender, baseline BMI, treatment duration, smoking status, 
current psychotropic drug and early weight gain (≥5%) groups. More details in 
Supplementary Material (paragraph 1.4.2). 
Short-term lipid changes and new onset dyslipidemia 
Kaplan-Meier estimates with log-rank tests, logistic mixed regression and Cox 
regression tests adjusting for variables mentioned below were used to compare the 
incidence of dyslipidemia development between early and non-early lipid change 
groups, i.e. TC ≥5% vs TC <5%, LDL-C ≥5% vs LDL-C <5%, TG ≥5% vs TG <5%, HDL-
C ≤-5% vs HDL-C >-5% and non-HDL-C ≥5% vs non-HDL-C <5%, using the survival 
package of R. More details in Supplementary Material (paragraph 1.4.3). Statistical 
significance was determined by a p-value ≤0.05. Statistical analyses were performed 
using Stata 12 (StataCorp, College Station TX, USA) and R environment for statistical 
computing version 3.3.1. 
 
 
 
 
 
 
 
 
RESULTS 
Demographics and evolution of metabolic parameters 
One hundred and eighty one patients who did not receive any lipid lowering agent 
during psychotropic treatment were included (Table 1, S2 Table). More details in 
Supplementary data (paragraph 2.1). 
Short-term lipid changes as predictors of long-term lipid changes in a discovery 
cohort 
For the selection of predictors, thresholds with the highest sensitivity combined with 
high area under the curve (AUC) values were chosen to maximize the detection of 
patients at high risk for important lipid profile worsening in the long-term. 
Early (i.e. after one month of psychotropic treatment) increase (≥5%) for TC, LDL-C TG 
and non-HDL-C and decrease (≥5%) for HDL-C were the best predictors for clinically 
relevant modifications of blood lipid levels after 3 months of treatment (≥30% TC, ≥40% 
LDL-C, ≥45% TG, ≥55% non-HDL-C increase and ≥20% HDL-C decrease; sensitivity 
70-100%, specificity 53-72%) (S3 Table) and one of best predictors after 12 months of 
treatment (S4 Table). More details in Supplementary data (paragraph 2.2). 
Demographic and clinical characteristics of the psychiatric discovery sample according 
to defined thresholds are shown in Table 1 (more details in Supplementary data 
(paragraph 2.3)). 
Confirmation of early lipid changes as predictors of long-term lipid changes 
The above-mentioned thresholds of 5% for TC, LDL-C, TG, non-HDL-C increase and 
5% for HDL-C decrease were confirmed as being significant predictors for subsequent 
increase of TC, LDL-C, TG and non-HDL-C, and of HDL-C decrease after 3 months of 
psychotropic treatment in linear mixed models (S5 Table). Patients exceeding early 
thresholds had 25% (p<0.0001) higher TC increase (TCi), 34% (p=0.0001) higher LDL-
C increase (LDLi), 40% (p=0.03) higher TG increase (TGi), 36% (p<0.0001) higher non-
HDL-C increase (non-HDLi) and 14% (p<0.0001) higher HDL-C decrease (HDLd) after 
3 months compared to patients who did not outreach such thresholds. Of note, some 
clinical variables were associated with these lipid changes as well (more details in 
Supplementary data (paragraph 2.4)).  
These early thresholds of lipid change were replicated in an independent psychiatric 
sample (S6 Table). In the replication sample, patients outreaching early thresholds had 
22%, 29%, 57%, 31% and 21% higher TCi, LDLi, TGi, non-HDLi and HDLd after 3 
and/or 12 months of psychotropic treatment compared to patients who did not 
(p≤0.003). 
Of note, patients exceeding early thresholds for TC, LDL-C, non-HDL-C and TG had a 
3% higher weight increase compared to patients who did not outreach such thresholds 
(p≤0.004; data not shown). 
 
Influence of early lipid thresholds on new onset dyslipidemia 
Demographic and clinical data of patients with no dyslipidemia at baseline, namely in 
patients who did not receive any lipid-lowering drugs at baseline and for whom baseline 
lipid levels were within normal range, are reported in S7 Table. An important proportion 
of patients developed NOD during the first year of psychotropic treatment (more 
information in Supplementary data).  
Incidence of NOD during treatment is displayed in Figure 1. It is noteworthy that 
survival rate curves sharply divided over time according to early threshold groups 
(Figure 2). Thus, the incidence of NOD was significantly higher in patients with TCi≥5%, 
LDLi≥5%, HDLd≥5%, TGi≥5% and non-HDLi≥5% compared to patients without early 
lipid changes (p=1*10-6; p=3*10-7; p=2*10-7; p=0.01 and p=1*10-3, respectively). These 
results were confirmed by Cox and logistic regressions and were replicated in an 
independent psychiatric sample for TCi≥5%, LDLi≥5% and non-HDLi ≥5% threshold 
groups (data not shown). S8 Table shows clinical risk factors associated with NODs. 
Apart from early lipid increase thresholds, some factors such as sex, early weight gain 
group and medication group were also associated with dyslipidemia incidence (S2 
Figure).  
Influence of the number of early lipid thresholds on new onset dyslipidemia 
S9 Table and Figure 3 display dyslipidemia incidence according to the number of early 
exceeded thresholds (EET) after the first month of treatment, namely according to the 
number of outreached lipid phenotype (either TCi≥5%, LDLi≥5%, TGi≥5% and/or 
HDLd≥5%). When developing one or more EET during the first month of treatment, the 
risk of developing dyslipidemia at a later stage in any of the four lipid variables was 
increased 14.4 fold, independently of the nature of EET. 
 
 
 
 
 
   
DISCUSSION 
The present study aimed to explore whether early lipid increase during the first month of 
psychotropic treatment may predict further important lipid increase and/or dyslipidemia 
development in patients receiving psychotropic drugs. In the present psychiatric sample, 
dyslipidemia prevalence of 37% for TC, 32% for LDL-C, 17% for HDL-C and 11% for TG 
were observed at baseline. These values are higher than those reported in the RAISE 
study (Recovery After an Initial Schizophrenia Episode) 17, possibly because of the 
shorter lifetime exposition to psychotropic treatment in the later (less than 6 months) 
than in the present psychiatric sample (around 8 years) and/or to the less stringent 
criterion used to define dyslipidemia in RAISE study. Nonetheless, in the present study 
a worsening of lipid parameters was observed during treatment despite of the high 
prevalence already observed at baseline, in parallel with a deterioration of other 
metabolic parameters. It is unlikely that the increase of dyslipidemia observed over time 
was due to a loss of follow-up of patients with no metabolic disturbances. Indeed, 
follow-up was required whatever the metabolic status of patients. In addition, an 
increase of dyslipidemia was observed after one month despite the same numbers of 
patients at both periods. This emphasizes the importance to prospectively monitor 
metabolic (including lipid) parameters during psychotropic treatment in all patients 
starting a psychotropic medication 16. Thus, the potential for psychotropic drugs to 
cause or to exacerbate metabolic syndrome in patients is not restricted to at-risk 
patients (e.g. drug naive, first episode disease, non-obese or young patients) 11. 
Because clinicians have been found to have a poor adherence to guidelines for 
metabolic monitoring worldwide 27-29, there is a need for programs to help educate 
providers and to facilitate monitoring of these cardiometabolic risk factors. Beside, a 
poor quality of management of potential physical health problems in psychiatric patients 
has also been recognized 28. For instance, a study investigating cardiometabolic risks in 
first-episode schizophrenic patients showed that only a small proportion of patients with 
dyslipidemia were treated with lipid-lowering agent, underlining an under-recognition of 
lipid abnormalities 17, which is consistent with other studies from Mitchell and 
collaborators 27, 30, 31 and with the low proportion (i.e. less than 10%) of patients with 
hyperlipidemia who receive lipid-lowering drugs in the present psychiatric sample. To 
date, no consensus has been established among clinicians with regard to thresholds of 
lipid increase that would need a reconsideration of the psychotropic treatment. 
Nevertheless, recent guidelines from the European Society of Cardiology and European 
Atherosclerosis Society were proposed for the management of dyslipidemia in patients 
receiving antipsychotics 32. These recommendations emphasize the importance of 
starting primary prevention earlier rather than later in psychiatric patients receiving 
psychotropic medication associated with metabolic disturbances 33. According to the 
National Institute for Health and Care Excellence (NICE) 34 and to the Joint British 
Societies 35 guidelines on the management of cardiovascular risk, all people with 
dyslipidemia should receive advice about diet, exercise, weight management and 
smoking cessation. If lifestyle advice is ineffective in normalizing the lipid profile, a statin 
should be considered after screening for the risk of cardiovascular disease 25. 
The present study showed that an early lipid increase of 5% or more for TC, LDL-C, TG 
and non-HDL-C and an early decrease of 5% or more for HDL-C were the best 
predictors for subsequent important lipid changes after 3 and 12 months of psychotropic 
treatment. These predictors displayed high sensitivities, meaning that among all truly at-
risk patients at 3 and 12 months, high percentages of patients were classified as being 
at risk during the first month of treatment. Additionally, these predictive models had high 
negative predictive values for the five lipid traits after 3 and 12 months, implying that 
most patients who did not reach early lipid threshold did not have substantial increase of 
lipid levels after 3 and 12 months of psychotropic treatment. Since a 1% reduction in 
LDL-C on average was shown to reduce risks for hard coronary heart disease events by 
approximately 1% in short-term controlled trials 23, our clinical predictive thresholds to 
prevent important lipid level increases appear clinically relevant. As from a clinical point 
of view, it is better to misclassify a patient in the high-risk group rather than to miss a 
truly high-risk patient, the present study aimed at maximizing sensitivity, with a lesser 
focus on specificity. Such as misclassification may result in possible unnecessary 
preemptive advices about diet, exercise, weight management and smoking cessation 
for low-risk patients identified as high risk, which can be considered beneficial whatever 
the metabolic status of the patient.  
The present findings are in agreement and expand those from a previous study in our 
Department, underlining the importance of a 5% weight increase during the first month 
of treatment to predict further important weight gain during longer-term treatment 13.  
Additionally, the present TG negative predictive value is in accordance with the results 
of a previous post-hoc randomized clinical trial reporting that a lack of early (i.e. from 6 
to 12 weeks) elevation in triglyceride concentration was predictive of later (i.e. from 24 
to 28 weeks) lack of substantial triglyceride increase in patients receiving olanzapine, 
ziprasidone or aripiprazole 21. Notably, predictors of a 5% increase in lipid levels were 
also significant in age-stratified, gender-stratified and medication-stratified subgroups of 
patients. These findings emphasize the robustness of these clinical predictors and 
should motivate clinicians to systematically monitor early lipid changes for each patient 
subgroups and not only in patients with known risk factors (e.g. young patients, 
women). Additional multivariate analyses showed that an early increase of weight (5% 
or more) 13 was not associated with longer-term lipid increases for TC, LDL-C, non-
HDL-C and TG, meaning that both lipids and weight should be monitored during 
treatment. These results are in accordance with a study that observed a lack of early 
predictive value of BMI to explain dyslipidemia on the long-term in patients receiving 
olanzapine and risperidone 36.  
In line with the expected metabolic effects, i.e. olanzapine, clozapine and valproate 
being associated with the highest risk of dyslipidemia, risperidone and quetiapine 
conferring an intermediate risk, and aripiprazole and amisulpride being at lower risk 37, 
the incidence of LDL-C dyslipidemia was significantly associated with risk-categorized 
drugs. Psychotropic drug categories were not associated with significant difference of 
dyslipidemia incidence for the remaining lipid phenotypes. This does not mean that the 
prescribed drugs did not have risk differences but rather underlines the relevance of the 
5% predictor independently of the drug prescribed. Of note, some studies have 
documented significant reductions in TC and LDL-C in patients treated with valproate 38, 
39. Additional analyses considering valproate as conferring a low risk for TC and LDL-C 
hyperlipidemia did not modify the present results (data not shown). Finally, the present 
study showed that patients who outreached one or more early lipid thresholds of 5% 
during the first month of treatment had a 14 fold risk of developing subsequent 
dyslipidemia, regardless of the nature of lipid phenotype, highlighting the need to 
implement clinical strategies to control long-term dyslipidemia. 
Of note, according to NICE guidelines 34, the consideration of non-HDL-C instead of 
LDL-C is regarded as more appropriate, because this gives a measure of all of the lipids 
that may promote arterial plaque production. In addition, LDL-C is not directly measured 
but requires a calculation using a fasting sample and for triglyceride levels to be less 
than 4.5 mmol/l, whereas the measurement of non-HDL-C does not. In the present 
study, non-HDL-C and LDL-C analyses provided consistent results, which strengthen 
the clinical predictive value of LDL-C. 
Several limitations of the present study need to be mentioned. Firstly, the majority of 
patients were not drug naive, and the observed lipid level increase may have resulted 
from past treatments. However, such patients constitute the majority of psychiatric 
populations, which therefore may even strengthen the clinical validity of the present 
findings. Secondly, the follow-up period lasted a median period of time of 378 days and 
even if most lipid trait worsening occurred within the period covered by the present 
study, it would be interesting to investigate the validity of these findings in longer-term 
treatment durations. Thirdly, environmental changes such as physical exercise or diet 
habits throughout the treatment, which could have influenced the evolution of lipid 
levels, were not available and their effects were not taken into account. Finally, although 
10 psychotropic drugs known as potentially leading to weight gain and/or worsening of 
other metabolic parameters were analyzed in the present study, the results cannot be 
extrapolated to other drugs. The major strength of this study is its longitudinal design 
with prospective monitoring of plasma lipid levels. In addition, the use of therapeutic 
drug monitoring allowed assessing patient adherence at each time of treatment, which 
is a critical issue to exclude false negatives (i.e. patients not taking the drug with no lipid 
increase).  
In conclusion, this study underlines the importance of metabolic monitoring following the 
introduction of antipsychotic drugs, mood stabilizers or some antidepressants for all 
patients, regardless of gender, age, baseline BMI and previous treatment history. Lipid 
level increases and a decrease of HDL-C by 5% or more during the first month of 
treatment should be used by clinicians as an early warning sign to consider such 
patients as being at higher risk for further important lipid level increases and/or 
dyslipidemia development during longer term treatment. Of note, we also previously 
demonstrated that a threshold of >5% weight gain could be used as the best predictor of 
important long-term weight gain. Clinical strategies such as preemptive lifestyle 
interventions should be implemented to prevent these adverse effects. The causative 
psychotropic drug should be replaced if clinically possible, after a careful evaluation of 
the risk-benefit ratio of a drug switch, considering the major impact of obesity and/or 
metabolic symptoms including dyslipidemia and their major consequences on morbidity 
and mortality. 
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